Physician profile
Yeisel Barquin
NPI 1407008576
$795.88
in general payments reported to CMS, 2019-2025
18 companies · $72.51 in 2025
The $72.51 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $165 · 2021: $36.04 · 2022: $38.85 · 2023: $23.91 · 2024: $34.41 · 2025: $72.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $275.84 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Kowa Pharmaceuticals America, INC. | $70.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $62.27 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $51.33 | 2019-2020 | |
| Abbvie INC. | $42.10 | 2025 | |
| Arbor Pharmaceuticals, INC. | $38.85 | 2022 | |
| Amarin Pharma, INC. | $37.94 | 2019-2020 | |
| Lilly USA, LLC | $34.19 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.68 | 2019 | |
| Ethicon US, LLC | $24.81 | 2020 | |
| Glaxosmithkline, LLC. | $20.36 | 2019 | |
| Sanofi Pasteur INC. | $19.31 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.87 | 2019 | |
| Allergan, INC. | $17.18 | 2020 | |
| Amgen INC. | $16.30 | 2024 | Otezla, Repatha |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalpropion Pharmaceuticals LLC | $14.70 | 2019 | |
| Currax Pharmaceuticals LLC | $12.11 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yeisel Barquin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.